Recardio

Regenerative Cardiac

  • About Us
    • Profile
    • Management
    • Boards
    • Awards
  • Science
    • Approach
    • Background
    • Therapy
  • Clinical
    • Phase 1
    • Phase 2B AMI
    • PHASE 3 (HEAL-AMI)
    • Phase 2B CHF
  • News Center

Phase 2B CHF

PHASE 2B STUDY IN CHF (REC-DUT-003)

The planned global multicenter, randomized, double blind, placebo controlled, parallel group study will evaluate the benefit of dutogliptin in combination with G-CSF as an adjunct treatment for patients with Heart Failure and reduced Ejection Fraction (HFrEF).

Status of Study

Planned to start in 2024.

Study Design

The double-blind, randomized, placebo-controlled study (Phase 2B) will evaluate both safety and efficacy of dutogliptin in combination with G-CSF as an adjunct treatment for patients with Heart Failure and reduced Ejection Fraction (HFrEF) of <40%. Patients will be in disease stage NYHA Class II and III (mild to marked symptoms and limitation during ordinary activity).

  • Contact us
  • Imprint
  • Data Privacy

© Recardio inc. 2023 · All Rights Reserved

Copyright © 2023 · Recardio on Genesis Framework · WordPress · Log in